Chemomab Therapeutics Ltd. (CMMB) has released an update.
Chemomab Therapeutics Ltd., a biotech company focused on fibro-inflammatory diseases, has been granted an additional 180 days by Nasdaq to meet the minimum bid price rule. The company’s shares will remain listed under the symbol ‘CMMB’ during this period, and if share prices hit $1.00 for 10 consecutive days, the compliance issue will be resolved. This extension is crucial for Chemomab as it continues to develop its leading drug candidate, CM-101, with positive clinical trial results and more data expected by mid-year 2024.
For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.
